Before completing this form, please refer to the [call](https://www.nihr.ac.uk/documents/global-effort-on-covid-19-geco-health-research-call-specification/24832) specification

If you have any queries concerning the application form and process please contact the NIHR CCF team for this funding opportunity on [geco@nihr.ac.uk](mailto:geco@nihr.ac.uk)

Section 1: Proposal Summary

|  |
| --- |
| 1.1 Title (max. 150 characters) |
|  |

|  |
| --- |
| 1.2 Scientific/technical summary (max. 2,000 characters approx. 250 words) |
|  |

|  |
| --- |
| 1.3. Plain English summary (max. 1,600 characters approx. 200 words)  A plain English summary is a clear and accessible explanation of your research. Further guidance on writing in plain English is available online at NIHR ‘[Make it clear](http://www.invo.org.uk/makeitclear/)’. |
|  |

|  |  |
| --- | --- |
| 1.4 Project duration\* | |
| Proposed start date (dd/mm/yy) |  |
| Proposed duration of award (months) |  |
| Proposed end date (dd/mm/yy) |  |

\* note max. 18 months

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 1.5 Project cost (£) | | |  | |  | |
|  | Total | UK (80%fEC) | | LMIC (100% direct cost, indirect cost see call specification) | | Non-UK, non-LIMC HIC\* (100% direct cost, see FAQs) |
| Staff costs |  |  | |  | |  |
| Consumables and other directly incurred costs |  |  | |  | |  |
| Travel costs |  |  | |  | |  |
| Indirect, directly allocated and estates costs (UK 80%fEC, LMIC see call specification) |  |  | |  | | N/A |
| **OVERALL TOTAL (£)** |  |  | |  | |  |

\*High Income Country

|  |  |  |
| --- | --- | --- |
| 1.6 Theme (referring to the call scope, please select a primary and if need a secondary theme most closely aligned to your proposal) | | |
|  | Primary | Secondary |
| Epidemiology - Transmission |  |  |
| Epidemiology - Disease Susceptibility and Severity |  |  |
| Epidemiology - Control and Mitigation |  |  |
| Clinical management - Natural history |  |  |
| Clinical management - Interventions |  |  |
| Clinical management - Health service delivery |  |  |
| Clinical management - Multimorbidity |  |  |
| Infection Prevention and control (IPC) - Movement control |  |  |
| IPC - PPE |  |  |
| IPC - Assessment and mitigation of control strategies |  |  |
| IPC - Role of the environment in transmission |  |  |
| IPC - Behavioural and cultural influence |  |  |
| IPC - Diagnostic tests |  |  |
| Social Science - Public Health |  |  |
| Social Science - Care, access and health systems |  |  |
| Social Science - Media and Communication |  |  |
| Social Science - Engagement |  |  |
| Other (specify) |  |  |

|  |
| --- |
| 1.7. ODA-eligible countries  Please list all country(s) on the [Development Assistance Committee (DAC) list](http://www.oecd.org/dac/stats/daclist.htm) of ODA-eligible countries where the proposed research will be of primary benefit. Also, please indicate (check the box below) if the proposed research will be of global benefit. |
| Global benefit |

|  |
| --- |
| 1.8. Justification of Resources (max. 2,000 characters approx. 250 words)  Provide justification of costs and details of how it provides value for money. |
|  |

|  |
| --- |
| 1.9. Keywords (please provide up to 10) |
|  |

Section 2: Investigator Details

|  |  |
| --- | --- |
| 2.1 Principal Investigator | |
| Name |  |
| PI Organisation and Country |  |
| PI Department |  |
| Email address |  |
| ORCID |  |
| Administrative authority contact name (email) |  |

|  |  |  |  |
| --- | --- | --- | --- |
| 2.2. Co-Investigators | |  |  |
| Name | Organisation | Country | Email address |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 2.3 Project Partners (unfunded by proposal, if applicable) | | | | |
| Project partner organisation | Project partner country | Project Partner Contact | Contribution Type (e.g. access to equipment, samples) | Value\* (£) |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

\*Please estimate approximate value of partner contribution

Section 3: Importance, Deliverables, Expertise, and Resources

|  |
| --- |
| 3.1 Please describe and justify the importance of the COVID-19 global health knowledge gap and/or need that you are targeting (max. 2,000 characters approx. 250 words)  Please provide details how you have identified the knowledge gap and what stakeholder engagement you have had in priority setting. |
|  |

|  |
| --- |
| 3.2. Please define the project’s deliverables and describe and justify how these will provide/lead to improve health and welfare of people in LMICs within 18 months (max. 2,000 characters approx. 250 words) |
|  |

|  |
| --- |
| 3.3. Please describe and justify how proposed work and deliverables are unique and value adding compared to existing COVID-19 activities targeting the same or similar knowledge gap(s) and/or need(s) (max. 2,000 characters approx. 250 words) |
|  |

|  |
| --- |
| 3.4. Please describe how you will be able to deliver the proposed research in the current climate of the COVID-19 pandemic (max. 2,000 characters approx. 250 words) |
|  |

|  |
| --- |
| 3.5. Please provide evidence that the team has the necessary expertise, track record and contacts to undertake the proposed work and ensure its impact to improve health and welfare of people living in LMIC (max. 2,000 characters approx. 250 words) |
|  |

|  |
| --- |
| 3.6. Please provide a brief description of the resources required in the different contributing environments (staff, materials, data, facilities etc.), including whether these are in hand, or if not, what gives you confidence that they will be accessible when required (max. 2,000 characters approx. 250 words) |
|  |

Section 4: Gender Equality

|  |
| --- |
| **4.1. Gender Equality: Outline how you have taken meaningful yet proportionate consideration as to how your proposed activities will contribute to reducing gender inequalities. (max. 2,000 characters approx. 250 words)** |
|  |

Section 5: Community Engagement and Involvement

|  |
| --- |
| 5.1 Where applicable, please describe:   1. how relevant community groups and organisations from low and middle income countries (LMICs) have been involved in developing this proposal; 2. the ways in which community groups and organisations, patients and carers will be actively involved in the proposed research, including any training and support provided.   If not applicable, please describe why (max. 2,000 characters approx. 250 words) |
|  |

Section 6: Detailed Research Plan

|  |
| --- |
| 6.1 Using all the headings in the order presented below, please use this section to clearly explain your proposed research (max. 16,000 characters approx. 2,000 words)   1. Aims and Objectives 2. Methodology 3. Training and Capacity Strengthening in LMICs 4. Dissemination, Outputs and anticipated impact 5. Project management / Governance (including Approach to Risk management and assurance / Safeguarding) |
|  |

Section 7: ODA Compliance Statement

|  |
| --- |
| 6.1 Please provide a statement that demonstrates how the proposal meets key ODA funding requirements. It should address the following questions:  i) which country(s) on the Organisation for Economic Cooperation and Development’s (OECD) Development Assistance Committee (DAC) list of ODA-eligible countries will directly benefit;  ii) how the application is directly and primarily relevant to the development challenges of those countries;  iii) how the outcomes will promote the health and welfare of people in the country or countries on the DAC list.  (max. 2,000 characters approx. 250 words) |
|  |

Annex 1: Regulatory requirements

A. Legislative/Ethical requirements

|  |  |
| --- | --- |
| Does this programme involve: | |
| **1. Animals?**  The use of vertebrate animals or other organisms covered by the [Animals (Scientific Procedures) Act 1986](https://www.gov.uk/guidance/research-and-testing-using-animals)[[1]](#footnote-1), whether or not it requires licensed procedures. | Yes/No |
| **1a. Animal Species?**  If animals are being used please provide the basic species information e.g. Mouse. |  |
| **2. Human Tissue?**  The use of human tissue as defined in the [Human Tissue Act 2004](https://mrc.ukri.org/research/facilities-and-resources-for-researchers/regulatory-support-centre/human-tissue/)[[2]](#footnote-2)? | Yes/No |
| **3. Stem Cells?**  Does the research involve the use of Stem Cells or regenerative medicine? | Yes-both/Yes-embryonic/Yes-adult/No |

Note: The MRC will make public information about animal experiments when needed (e.g. as anonymous examples, or in response to direct queries) but will resist all requests for information that might lead to the identification of places or individuals, except with the express permission of the individuals concerned.

B. Additional information for clinical research

|  |  |
| --- | --- |
| Does this programme involve: | |
| **1. Human participation?**  Research which requires *face-to-face* contact with *patients*, or with *healthy human participants* (by holders of a clinical contract) and may involve use of patient records as a concomitant, e.g. a clinical trial. | Yes/No |
| **2. Records based studies?**  Research which requires *access to personal data* on health or lifestyle *without* involving face-to-face contact with any people, e.g. public health interventions, health economic studies, epidemiological studies, health services research and meta-analyses - information may be obtained by telephone, postal questionnaires/surveys or electronic/manual data retrieval. | Yes/No |
| **3. Clinical samples?**  Research which involves *laboratory studies* on *human material* which are specifically designed to understand or treat a disease/disorder. N.B. Basic biomedical research remote from application to a disease/disorder, such as the use of immortalised human cell lines in model biological systems, is excluded. | Yes/No |
| **4. Technology development for clinical use?**  Development or adaptation of technologies for diagnosis or therapy, e.g. instrument development for diagnostic or surgical use; development of new techniques, such as photodynamic therapy, for clinical use. | Yes/No |

Note: This information will not be made publicly available in an identifiable format.

C. Other ethical requirements

|  |  |
| --- | --- |
| Ethical, safeguarding and/or health and safety issues: | |
| **1.** Have any other ethical, safeguarding and/or health and safety issues been identified for the proposed research? If yes, please ensure these are addressed in Section 6 – Detailed Research Plan | Yes/No |
| **2b.** Is there already ethical approval in place? | Yes/No |
| **2.** If not, has/will ethical approval be sought? | Yes/No |

D. Additional Analysis Data

|  |  |
| --- | --- |
| The following data will assist us in scientific and strategic reporting and may be published. | |
| **Research Setting**  Based on direct patient contact, indicate whether the research involves a particular medical setting such as primary care or secondary care. | None/Other/Emergency/Primary & Secondary/Secondary/Primary |

Annex 2: Funder principles for supporting research in low- and middle-income countries for epidemics & pandemics

The UKCDR Funder Principles were launched in The Lancet on 17 July 2020 ["Strengthening the global effort on COVID-19 research through joint principles for funding global research in epidemics and pandemics".](https://www.thelancet.com/action/showPdf?pii=S0140-6736(20)31598-1)

Please read the announcement from UKCDR: ["UKCDR & GloPID-R align research funders to seven principles for stronger research response to epidemics & pandemics".](https://www.ukcdr.org.uk/news-article/ukcdr-glopid-r-align-research-funders-to-seven-principles-for-stronger-research-response-to-epidemics-pandemics/)

1. <http://www.homeoffice.gov.uk/science-research/animal-research/> [↑](#footnote-ref-1)
2. <https://mrc.ukri.org/research/facilities-and-resources-for-researchers/regulatory-support-centre/human-tissue/> [↑](#footnote-ref-2)